Drugs in MeSH Category Anthelmintics

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Elizabeth	ALBENDAZOLE	albendazole	TABLET;ORAL	208094-001	May 20, 2019	AB	RX	No	No
Alembic	ALBENDAZOLE	albendazole	TABLET;ORAL	215652-001	Sep 4, 2024	AB	RX	No	No
Bayer Hlthcare	BILTRICIDE	praziquantel	TABLET;ORAL	018714-001	Dec 29, 1982		DISCN	Yes	No
Cipla Ltd	ALBENDAZOLE	albendazole	TABLET;ORAL	210434-001	Sep 21, 2018		DISCN	No	No
Impax Labs Inc	ALBENZA	albendazole	TABLET;ORAL	020666-001	Jun 11, 1996		DISCN	Yes	No

Anthelmintics Market Analysis and Financial Projection

The global anthelmintics market is experiencing steady growth driven by rising parasitic infections and innovations in drug development, while its patent landscape reflects ongoing efforts to address therapeutic challenges like drug resistance. Below is a detailed analysis:

---

Market Dynamics

Growth Projections

• The market valuation shows regional reporting variations but consistent growth:
  • $3.62 billion (2024) → $7.1 billion by 2032 (CAGR 8.42%) [1]
  • $3.16 billion (2024) → $4.11 billion by 2029 (CAGR 5.3%) [11]
  • $2.75 billion (2023) → $3.85 billion by 2032 (CAGR 3.8%) [8]

Key Drivers

1. High Infection Burden: Soil-transmitted helminths infect 1.5 billion people globally (24% of the world’s population), driving demand for treatments[2].
2. Livestock and Zoonotic Risks: Over 50% of parasitic infections in animals (e.g., tapeworms, roundworms) require anthelmintics, with growing emphasis on zoonotic disease prevention[13].
3. Geographical Hotspots: Asia-Pacific is the fastest-growing region due to poor sanitation in densely populated areas like India and Southeast Asia[2][8][11].

Market Segmentation

Segment	Dominant Category	Fastest-Growing Category
Drug Class	Benzimidazoles (e.g., albendazole)	Macrocyclic lactones (e.g., ivermectin) [2][11]
Infection Type	Nematode infections	Trematode infections
Distribution	Hospital pharmacies	Online pharmacies

Regional Revenue Share (2023–2032)

Region	CAGR	Key Factors
North America	2.5–5.6%	High healthcare spending and diagnostic adoption[5][11]
Asia-Pacific	6.3%	Government deworming programs and rising pet ownership[2][8]

---

Patent Landscape

Key Trends

1. Focus on Stability: Patents like US7396819B2 and WO2005016357A1 address ivermectin’s hygroscopic nature through spray granulation and polyethylene glycol-based formulations[10][12].
2. Combination Therapies: Innovations combining ivermectin with praziquantel or pyrantel enhance efficacy against resistant strains[10][12].
3. Resistance Management: Over 50% of patents filed between 1985–2008 targeted drug resistance, but activity plateaued post-2008[6].

Geographical Distribution

• Top Patent Holders: U.S. (6,154 patents) and China (2,423 patents) lead filings[6].
• Stagnation Concerns: Nearly 50% of patents for NTDs like schistosomiasis are inactive, reflecting low commercial incentives despite high disease burden[6].

Notable Patents

Patent Number	Drug/Technology	Innovation Focus
3,657,267	Mebendazole	Benzimidazole carbamate formulations[9]
US7396819B2	Ivermectin + praziquantel	Stabilized solid-dose combinations[10]

---

Challenges and Opportunities

Major Barriers

• Drug Resistance: Overuse in livestock has led to resistant helminth strains, particularly in benzimidazole and macrocyclic lactone classes[4][13].
• R&D Funding Gaps: Only 6% of patents involve NGOs or public-private partnerships, slowing innovation for low-income markets[6].

Future Directions

• Next-Gen Therapies: CRISPR-based treatments and nanoparticle drug delivery systems are under exploration[13].
• One Health Initiatives: Integrating human and veterinary markets to address zoonotic transmission risks[13].

---

"The filing pattern of patent families analyzed reveals slow progress on R&D for neglected tropical diseases. Involving new players, such as non-governmental organizations, may help mitigate this burden." – PMC Study on NTD Patents[6]

---

The anthelmintics market remains critical for global health, with growth hinging on equitable drug access and sustainable innovation. Strategic patenting and cross-sector collaboration will determine its capacity to combat evolving parasitic threats.

References

1. https://www.databridgemarketresearch.com/es/reports/global-anthelmintics-market/market-analysis
2. https://www.alliedmarketresearch.com/anthelmintic-drugs-market-A11501
3. https://www.youtube.com/watch?v=o6CTfdx85ys
4. https://www.globenewswire.com/news-release/2024/09/05/2941132/32656/en/Anthelmintic-Drugs-Market-Projected-Growth-at-3-9-CAGR-to-Reach-USD-3-7-billion-by-2031-Exclusive-Research-Report-by-Transparency-Market-Research-Inc.html
5. https://www.cognitivemarketresearch.com/anthelmintic-drugs-market-report
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC5686799/
7. https://meshb.nlm.nih.gov/record/ui?ui=D000871
8. https://www.zionmarketresearch.com/report/anthelmintic-drugs-market
9. https://www.drugpatentwatch.com/p/patent/3657267
10. https://patents.google.com/patent/US7396819B2/en
11. https://www.thebusinessresearchcompany.com/report/anthelmintic-drugs-global-market-report
12. https://patents.google.com/patent/WO2005016357A1/en
13. https://www.verifiedmarketreports.com/blog/top-7-trends-in-the-anthelmintic-drugs-market/